Workflow
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DexComDexCom(US:DXCM) ZACKSยท2025-07-31 13:51

Core Insights - DexCom, Inc. (DXCM) reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, exceeding the Zacks Consensus Estimate of 45 cents by 6.7% and up from 43 cents in the prior-year quarter [2] - Total revenues grew 15.2% year over year to $1.16 billion, driven by strong category demand and recent access wins, particularly for type 2 diabetes [3][8] - Despite positive results, DXCM shares declined nearly 5.5% in after-hours trading on July 30, although the stock has gained 9.9% year to date [4] Revenue Details - Sensor and other revenues, which account for 97% of total revenues, increased 18% year over year to $1.12 billion, while hardware revenues decreased 31% to $39.3 million [6] - U.S. revenues (73% of total revenues) rose 15% year over year to $841 million, and international revenues (27%) improved 16% to $316.1 million [7] Margin Analysis - Adjusted gross profit totaled $695.9 million, up 9.1% from the prior-year quarter, with an adjusted gross margin of 60.1%, down 340 basis points year over year [9][10] - Total adjusted operating income was $221.8 million, reflecting a 13.5% increase from the prior-year period [10] Financial Position - DexCom ended the second quarter with cash, cash equivalents, and marketable securities worth $2.93 billion, up from $2.7 billion in the first quarter of 2025 [11] - Total assets amounted to $7.33 billion, an increase from $6.75 billion sequentially [11] 2025 Guidance - The company raised its revenue outlook for 2025 to a range of $4.6-$4.625 billion, implying 14-15% year-over-year growth [12] - Adjusted gross margin is expected to be approximately 62%, with adjusted operating margin projected at around 21% [12] Product and Market Developments - DexCom is set to launch the 15-day G7 sensor in the second half of 2025, with ongoing development of the next-gen G8 platform [15] - The company has seen strong new customer additions due to expanded reimbursement for type 2 diabetes, and international momentum is supported by key coverage wins [14][18] Management Transition - Current CEO Kevin Sayer will step down in early 2026, with Jake Leach, a long-time executive, set to take over [17]